{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:52:43Z","timestamp":1782150763051,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,30]]},"DOI":"10.7759\/cureus.38348","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T21:08:07Z","timestamp":1682888887000},"source":"Crossref","is-referenced-by-count":3,"title":["Valproate-Associated Transaminitis and Rhabdomyolysis"],"prefix":"10.7759","author":[{"given":"Anupam","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannlis","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Dew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen CU","year":"2003","unstructured":"Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003, 9:199-216. 10.1111\/j.1527-3458.2003.tb00249.x","journal-title":"CNS Drug Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259935","article-title":"Valproate-associated hepatotoxicity and its biochemical mechanisms","volume":"3","author":"Eadie MJ","year":"1988","unstructured":"Eadie MJ, Hooper WD, Dickinson RG. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol Adverse Drug Exp. 1988, 3:85-106. 10.1007\/BF03259935","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108970","article-title":"Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase","volume":"9","author":"Star K","year":"2014","unstructured":"Star K, Edwards IR, Choonara I. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase. PLoS One. 2014, 9:e108970. 10.1371\/journal.pone.0108970","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27712","article-title":"Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model","volume":"61","author":"Li S","year":"2015","unstructured":"Li S, Guo J, Ying Z, et al.. Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology. 2015, 61:1730-9. 10.1002\/hep.27712","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000020651","article-title":"Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin","volume":"8","author":"Holt S","year":"2000","unstructured":"Holt S, Moore K. Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol. 2000, 8:72-6. 10.1159\/000020651","journal-title":"Exp Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1042\/bj2810021","article-title":"Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis","volume":"281 ( Pt 1)","author":"Wallimann T","year":"1992","unstructured":"Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J. 1992, 281 ( Pt 1):21-40. 10.1042\/bj2810021","journal-title":"Biochem J"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/S0889-857X(21)00069-7","article-title":"Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis","volume":"20","author":"Bohlmeyer TJ","year":"1994","unstructured":"Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am. 1994, 20:845-56.","journal-title":"Rheum Dis Clin North Am"},{"key":"ref8","article-title":"Valproate induced myopathy-a different presentation of an uncommon condition","volume":"3","author":"Mittal SH","year":"2018","unstructured":"Mittal SH,  Pai S, ZK, Misri ZK, Pai R. Valproate induced myopathy-a different presentation of an uncommon condition. Manipal J Med Sci. 2018, 3:2.","journal-title":"Manipal J Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/cc3742","article-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?","volume":"9","author":"Lheureux PE","year":"2005","unstructured":"Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?. Crit Care. 2005, 9:431-40. 10.1186\/cc3742","journal-title":"Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80294-8","article-title":"Drug-induced myopathies","volume":"5","author":"JS Le Quintrec","year":"1991","unstructured":"JS Le Quintrec, JL. Le Quintrec. Drug-induced myopathies. Baillieres Best Pract Res Clin Rheumatol. 1991, 5:21-38. 10.1016\/S0950-3579(05)80294-8","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.69.811.333","article-title":"Drug-induced rhabdomyolysis--mechanisms and management","volume":"69","author":"Prendergast BD","year":"1993","unstructured":"Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J. 1993, 69:333-6. 10.1136\/pgmj.69.811.333","journal-title":"Postgrad Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011412.pub2","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"6","author":"Nevitt SJ","year":"2017","unstructured":"Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017, 6:CD011412. 10.1002\/14651858.CD011412.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132045-valproate-associated-transaminitis-and-rhabdomyolysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:12Z","timestamp":1707508632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132045-valproate-associated-transaminitis-and-rhabdomyolysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,30]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.38348","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,30]]}}}